Lin Jinhai, Zhong Bin, Yan Jinling, Chen Lili
Department of Pharmacy, The First Affiliated Hospital of Gannan Medical University, Ganzhou 341000, China.
Cell Mol Biol (Noisy-le-grand). 2020 May 16;66(2):198-203.
This experiment aimed to study the effect of trimetazidine combined with perindopril on NT-proBNP levels in rats with dilated cardiomyopathy (DCM). 40 SD rats were selected and 10 rats were randomly selected to continue to be fed as the blank group. The other 30 rats were injected with adriamycin to establish the DCM rat model. Then they were divided into 3 groups, namely control group (without any drug intervention), trimetazidine group (with trimetazidine single-agent intervention) and combination drug group (with trimetazidine combined with perindopril intervention), with 10 DCM rats in each group. After 4 weeks of intervention, left ventricular ejection fraction (LVEF), left ventricular end-diastolic dimension (LVEDD) and left ventricular end-systolic diameter (LVESD) of rats were measured by echocardiography. The changes of plasma brain natriuretic peptide (BNP) level and n-terminal pro-brain natriuretic peptide (NT-proBNP) were detected by ELISA. RT-PCR was used to detect the regulation of angiotensin II type 1 receptor (AT1Rs) and lamin A mRNA expression in rat myocardium. After the intervention, the LVEF%, LVEDD and LVESD measured values of the rats in the combination drug group were significantly better than those in the trimetazidine group and the control group (P< 0.05). The BNP, NT-proBNP and AT1Rs levels of the rats in the combination drug group were significantly lower than those in the trimetazidine group and the control group. The difference was statistically significant (p< 0.05). The lamin A expression of the rats in the combination drug group was significantly higher than that in the trimetazidine group and the control group. The difference was statistically significant (P< 0.05). Compared with trimetazidine single-agent, trimetazidine combined with perindopril can significantly improve the cardiac function of rats with dilated cardiomyopathy, reduce the serum NT-proBNP level and improve the expression of AT1Rs and lamin A in rats.
本实验旨在研究曲美他嗪联合培哚普利对扩张型心肌病(DCM)大鼠N末端B型利钠肽原(NT-proBNP)水平的影响。选取40只SD大鼠,随机选取10只大鼠继续饲养作为空白组。其余30只大鼠注射阿霉素建立DCM大鼠模型。然后将其分为3组,即对照组(无任何药物干预)、曲美他嗪组(曲美他嗪单药干预)和联合用药组(曲美他嗪联合培哚普利干预),每组10只DCM大鼠。干预4周后,采用超声心动图测量大鼠左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)和左心室收缩末期内径(LVESD)。采用酶联免疫吸附测定法(ELISA)检测血浆脑钠肽(BNP)水平和N末端脑钠肽原(NT-proBNP)的变化。采用逆转录聚合酶链反应(RT-PCR)检测大鼠心肌组织中血管紧张素Ⅱ1型受体(AT1Rs)和核纤层蛋白A(lamin A)mRNA的表达调控情况。干预后,联合用药组大鼠的LVEF%、LVEDD和LVESD测量值均显著优于曲美他嗪组和对照组(P<0.05)。联合用药组大鼠的BNP、NT-proBNP和AT1Rs水平均显著低于曲美他嗪组和对照组。差异具有统计学意义(p<0.05)。联合用药组大鼠的lamin A表达显著高于曲美他嗪组和对照组。差异具有统计学意义(P<0.05)。与曲美他嗪单药相比,曲美他嗪联合培哚普利可显著改善扩张型心肌病大鼠的心功能,降低血清NT-proBNP水平,并改善大鼠AT1Rs和lamin A的表达。